As Ranbaxy readies to launch novel synthetic antimalarial, Cipla-DNDi unveil artesunate FDC
This article was originally published in Scrip
Executive Summary
Even as Ranbaxy is expected to unveil what is expected to be India's first new chemical entity (NCE) for malaria on 25 April, competitor Cipla said it was ready to introduce a fixed-dose combination of artesunate and mefloquine in collaboration with Drugs for Neglected Diseases Initiative (DNDi) for the treatment of uncomplicated Plasmodium falciparum malaria.